Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Bearish
7
Neutral
2
Bullish
5
Bearish
7
Neutral
6
Bullish
33
Bearish
0
Neutral
4
Bullish
28
Discovery themes featuring this stock
Anlon Healthcare manufactures pharmaceutical APIs and high‑purity intermediates from its Rajkot facility, provides custom manufacturing (CDMO) services, and has expanded via an IPO in August 2025; the company reports regulatory filings including 21 DMFs and commercial presence across 15 countries, positioning Anlon Healthcare as a research-driven API/intermediate manufacturer focused on regulated market customers.
The company reported a sharp year‑on‑year operational improvement: Q3 total income rose to INR 35.78 crore from INR 9.38 crore a year earlier, EBITDA of INR 12.54 crore at 35.1% margin and a return to PAT of INR 5.15 crore, reflecting stronger product mix, operating leverage and an expanding CDMO pipeline for Anlon Healthcare.
Anlon Healthcare is pursuing a sizeable inorganic and organic expansion plan: management completed the Apiqo Organics deal, is proposing Bizotic Life Science acquisition, and announced greenfield/organic expansions with planned capital expenditure of about INR 100–120 crore to materially increase installed capacity and support projected revenue growth for Anlon Healthcare.
The company emphasises regulatory and product pipeline progress: management has 21 DMFs filed, expects commercialisation of several DMF products next year, is developing three CDMO molecules for global innovators with validations underway, and targets broader regulated‑market penetration and new API launches to diversify Anlon Healthcare's therapeutic exposure and margin profile.
Pharmaceuticals & Biotechnology
Pharmaceuticals
756 Cr
Low Risk
18.2
32.3
0.2
3.5
172.00
86.98
Sales CAGR
Profit CAGR
ROE
ROCE
Anlon Healthcare Ltd (AHCL) is currently trading at 141.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anlon Healthcare manufactures pharmaceutical APIs and high‑purity intermediates from its Rajkot facility, provides custom manufacturing (CDMO) services, and has expanded via an IPO in August 2025; the company reports regulatory filings including 21 DMFs and commercial presence across 15 countries, positioning Anlon Healthcare as a research-driven API/intermediate manufacturer focused on regulated market customers. The company reported a sharp year‑on‑year operational improvement: Q3 total income rose to INR 35.78 crore from INR 9.38 crore a year earlier, EBITDA of INR 12.54 crore at 35.1% margin and a return to PAT of INR 5.15 crore, reflecting stronger product mix, operating leverage and an expanding CDMO pipeline for Anlon Healthcare. Anlon Healthcare is pursuing a sizeable inorganic and organic expansion plan: management completed the Apiqo Organics deal, is proposing Bizotic Life Science acquisition, and announced greenfield/organic expansions with planned capital expenditure of about INR 100–120 crore to materially increase installed capacity and support projected revenue growth for Anlon Healthcare. The company emphasises regulatory and product pipeline progress: management has 21 DMFs filed, expects commercialisation of several DMF products next year, is developing three CDMO molecules for global innovators with validations underway, and targets broader regulated‑market penetration and new API launches to diversify Anlon Healthcare's therapeutic exposure and margin profile.
Over the past 52 weeks, Anlon Healthcare Ltd has traded between a low of ₹86.98 and a high of ₹172.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anlon Healthcare Ltd has a market capitalization of approximately 755.81. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anlon Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.24 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 755.81 Cr, Anlon Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anlon Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anlon Healthcare Ltd is 18.24. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1180.00 | 836 Cr | -27.00 | 2.53 | 0.08 | -1.63 | -0.95 | -4.97 | ||
83.27 | 831 Cr | -44.10 | 2.40 | 0.55 | -7.10 | -3.47 | -2.99 | ||
73.90 | 830 Cr | 17.70 | 2.54 | 0.91 | 11.84 | 15.90 | 8.22 | ||
155.60 | 771 Cr | 45.50 | 1.54 | 1.88 | 3.51 | 5.38 | 2.04 | ||
116.20 | 756 Cr | 18.24 | 3.53 | 0.00 | 18.61 | 20.31 | 11.20 | ||
635.00 | 752 Cr | 9.74 | 2.94 | 0.12 | 10.92 | 16.89 | 7.42 | ||
469.65 | 685 Cr | 33.36 | 4.46 | 0.00 | 13.30 | 16.18 | 8.86 | ||
| Median: 7 Co. | — | 155.60 | 771 Cr | 17.70 | 2.54 | 0.12 | 10.92 | 15.90 | 7.42 |
Share Purchase Agreement
Anlon Healthcare approved a share purchase agreement dated Apr 16, 2026 to acquire 63.98% of Remember India Health Links Pvt Ltd for cash, making it a subsidiary; expected to complete within 4–5 months; target FY25 turnover Rs.83.08 lakh.
Majority stake acquisition
Anlon Healthcare approved acquisition of 1,11,00,000 shares (63.98%) of Remember India Health Links Pvt Ltd for Rs.5,38,12,800 (cash) via SPA dated Apr 16, 2026; target (turnover Rs.83.08L as on 31-03-2025) to become subsidiary; completion in ~4–5 months.
Acquisition of Subsidiary
ANLON Healthcare approved acquisition of 1,11,00,000 equity shares (63.98%) of Remember India Health Links Pvt Ltd for Rs.5,38,12,800 in cash; on completion the target will become a subsidiary to expand into finished dosage formulations.
